2026 U.S. ENDS market and brand watch
A source-led record of material federal events that change what B2B procurement teams should verify—not a popularity ranking, sales forecast or availability list.
FDA activity in 2026 reinforces exact-product review: check the live FDA record and order documents, distinguish final actions from drafts or proposals, and never infer authorization for a brand family from one named SKU.
Material 2026 events
May 5: FDA granted marketing orders for four Glas ENDS products
FDA announced marketing authorization for four specifically named Glas e-liquid pods: Classic Menthol, Fresh Menthol, Gold and Sapphire. The action applies to those products, not every Glas product and not other brands or catalogue entries. Buyers should confirm each exact record in the FDA database and read the linked order material. Primary source: FDA, May 5, 2026.
May 8: FDA issued an enforcement-priorities guidance
FDA described circumstances affecting its enforcement priorities for certain unauthorized ENDS and nicotine-pouch products. FDA expressly noted that falling within an enforcement policy does not indicate that a product is likely to receive authorization. Procurement teams should not treat enforcement discretion, a pending application or inclusion on a policy-related list as a marketing order. Primary source: FDA, May 8, 2026.
March 11 / April 8: FDA published draft guidance for flavored ENDS applications
The draft discusses FDA's current thinking on youth risk and evidence of adult benefit in flavored ENDS PMTA review. It is draft guidance, not a marketing authorization and not a final rule. Buyers should track final agency action rather than convert application policy into a product-status claim. Primary source: FDA notice, April 8, 2026.
June 26: FDA proposed foreign-manufacturer registration requirements
FDA announced a proposed rule that, if finalized, would require foreign tobacco-product manufacturers to register and provide product information before importing into the United States. Because this is a proposal, procurement teams should monitor the rulemaking and should not describe the proposed requirements as already effective. Primary source: FDA, June 26, 2026.
Brand mention here records an official event only. It does not imply KKFOG availability, distribution rights, endorsement, product equivalence or authorization of any other SKU.
How buyers should use this watch
Recheck the live record
Use the FDA database at the time of review; dated articles can become stale.
Match exact identities
Record manufacturer, product name, model, strength and linked order documents before commercial discussion.
Separate status from sourcing
Authorization, supplier availability, distribution rights and destination requirements are distinct questions.
This monitored update is educational procurement information, not legal advice. Use the full verification checklist and consult qualified counsel or the relevant authorities.